Cargando…
Validity and reliability of the Neurodevelopmental Screening Tool (NDST) in screening for neurodevelopmental disorders in children living in rural Kenyan coast
Background: There are no data on the precise burden of neurodevelopmental disorders (NDD) in Africa, despite high incidence of risk factors. Ten Questions Questionnaire (TQQ) has been used extensively in Africa to screen neurological impairments but not autism spectrum disorders (ASD) and attention-...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503789/ https://www.ncbi.nlm.nih.gov/pubmed/34676305 http://dx.doi.org/10.12688/wellcomeopenres.16765.1 |
_version_ | 1784581202210979840 |
---|---|
author | Bitta, Mary A. Kipkemoi, Patricia Kariuki, Symon M. Abubakar, Amina Gona, Joseph Philips-Owen, Jacqueline Newton, Charles R. |
author_facet | Bitta, Mary A. Kipkemoi, Patricia Kariuki, Symon M. Abubakar, Amina Gona, Joseph Philips-Owen, Jacqueline Newton, Charles R. |
author_sort | Bitta, Mary A. |
collection | PubMed |
description | Background: There are no data on the precise burden of neurodevelopmental disorders (NDD) in Africa, despite high incidence of risk factors. Ten Questions Questionnaire (TQQ) has been used extensively in Africa to screen neurological impairments but not autism spectrum disorders (ASD) and attention-deficit hyperactivity disorders (ADHD). The Neurodevelopmental Screening Tool (NDST) has reliably assessed NDD in Asia; its validity in Africa is unknown. Methods: Using NDST and TQQ, we screened 11,223 children aged 6-9 years in Kilifi, Kenya. We invited all screen-positives and a proportion of screen-negative children for confirmatory diagnosis of NDD using clinical history, neuropsychological assessments and interviews. Results: In total, 2,245 (20%) children screened positive for NDD. Confirmatory testing was completed for 1,564 (69.7%) screen-positive and 598 (6.7%) screen-negative children. NDST’s sensitivity was 87.8% (95%CI: 88.3-88.5%) for any NDD, 96.5% (95%CI:96.1-96.8%) ASD and 89.2% (95%CI: 88.7-89.8%) for ADHD. Moderate/severe neurological impairments’ sensitivities ranged from 85.7% (95%CI: 85.1-86.3%) for hearing impairments to 100.00% (100.0-100.0%) for motor impairments. NDST had higher sensitivities than TQQ for epilepsy (88.8 vs 86.7), motor impairments (100.0 vs 93.7) and cognitive impairment (88.2 vs 84.3). Sensitivities for visual and hearing impairments were comparable in both tools. NDST specificity was 82.8% (95%CI: 82.1-83.5%) for any NDD, 94.5% (95%CI: 94.0-94.9%) for ASD and 81.7% (95%CI: 81.0-82.4%) for ADHD. The specificities range for neurological impairments was 80.0% (95%CI: 79.3-80.7%) for visual impairments to 93.8% (95%CI: 93.4-94.3%) for epilepsy. Negative predictive values were generally very high (≤100%), but most positive predictive values (PPV) were low (≤17.8%). Domain specific internal consistency ranged from 0.72 (95%CI: 0.70-0.74) for ADHD to 0.89 (95%CI: 0.87-0.90) for epilepsy. Conclusions: NDST possesses high sensitivity and specificity for detecting different domains of NDD in Kilifi. Low PPV suggest that positive diagnoses should be confirmed when samples are drawn from a population with low disease prevalence. |
format | Online Article Text |
id | pubmed-8503789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | F1000 Research Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-85037892021-10-20 Validity and reliability of the Neurodevelopmental Screening Tool (NDST) in screening for neurodevelopmental disorders in children living in rural Kenyan coast Bitta, Mary A. Kipkemoi, Patricia Kariuki, Symon M. Abubakar, Amina Gona, Joseph Philips-Owen, Jacqueline Newton, Charles R. Wellcome Open Res Research Article Background: There are no data on the precise burden of neurodevelopmental disorders (NDD) in Africa, despite high incidence of risk factors. Ten Questions Questionnaire (TQQ) has been used extensively in Africa to screen neurological impairments but not autism spectrum disorders (ASD) and attention-deficit hyperactivity disorders (ADHD). The Neurodevelopmental Screening Tool (NDST) has reliably assessed NDD in Asia; its validity in Africa is unknown. Methods: Using NDST and TQQ, we screened 11,223 children aged 6-9 years in Kilifi, Kenya. We invited all screen-positives and a proportion of screen-negative children for confirmatory diagnosis of NDD using clinical history, neuropsychological assessments and interviews. Results: In total, 2,245 (20%) children screened positive for NDD. Confirmatory testing was completed for 1,564 (69.7%) screen-positive and 598 (6.7%) screen-negative children. NDST’s sensitivity was 87.8% (95%CI: 88.3-88.5%) for any NDD, 96.5% (95%CI:96.1-96.8%) ASD and 89.2% (95%CI: 88.7-89.8%) for ADHD. Moderate/severe neurological impairments’ sensitivities ranged from 85.7% (95%CI: 85.1-86.3%) for hearing impairments to 100.00% (100.0-100.0%) for motor impairments. NDST had higher sensitivities than TQQ for epilepsy (88.8 vs 86.7), motor impairments (100.0 vs 93.7) and cognitive impairment (88.2 vs 84.3). Sensitivities for visual and hearing impairments were comparable in both tools. NDST specificity was 82.8% (95%CI: 82.1-83.5%) for any NDD, 94.5% (95%CI: 94.0-94.9%) for ASD and 81.7% (95%CI: 81.0-82.4%) for ADHD. The specificities range for neurological impairments was 80.0% (95%CI: 79.3-80.7%) for visual impairments to 93.8% (95%CI: 93.4-94.3%) for epilepsy. Negative predictive values were generally very high (≤100%), but most positive predictive values (PPV) were low (≤17.8%). Domain specific internal consistency ranged from 0.72 (95%CI: 0.70-0.74) for ADHD to 0.89 (95%CI: 0.87-0.90) for epilepsy. Conclusions: NDST possesses high sensitivity and specificity for detecting different domains of NDD in Kilifi. Low PPV suggest that positive diagnoses should be confirmed when samples are drawn from a population with low disease prevalence. F1000 Research Limited 2021-06-02 /pmc/articles/PMC8503789/ /pubmed/34676305 http://dx.doi.org/10.12688/wellcomeopenres.16765.1 Text en Copyright: © 2021 Bitta MA et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Bitta, Mary A. Kipkemoi, Patricia Kariuki, Symon M. Abubakar, Amina Gona, Joseph Philips-Owen, Jacqueline Newton, Charles R. Validity and reliability of the Neurodevelopmental Screening Tool (NDST) in screening for neurodevelopmental disorders in children living in rural Kenyan coast |
title | Validity and reliability of the Neurodevelopmental Screening Tool (NDST) in screening for neurodevelopmental disorders in children living in rural Kenyan coast |
title_full | Validity and reliability of the Neurodevelopmental Screening Tool (NDST) in screening for neurodevelopmental disorders in children living in rural Kenyan coast |
title_fullStr | Validity and reliability of the Neurodevelopmental Screening Tool (NDST) in screening for neurodevelopmental disorders in children living in rural Kenyan coast |
title_full_unstemmed | Validity and reliability of the Neurodevelopmental Screening Tool (NDST) in screening for neurodevelopmental disorders in children living in rural Kenyan coast |
title_short | Validity and reliability of the Neurodevelopmental Screening Tool (NDST) in screening for neurodevelopmental disorders in children living in rural Kenyan coast |
title_sort | validity and reliability of the neurodevelopmental screening tool (ndst) in screening for neurodevelopmental disorders in children living in rural kenyan coast |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503789/ https://www.ncbi.nlm.nih.gov/pubmed/34676305 http://dx.doi.org/10.12688/wellcomeopenres.16765.1 |
work_keys_str_mv | AT bittamarya validityandreliabilityoftheneurodevelopmentalscreeningtoolndstinscreeningforneurodevelopmentaldisordersinchildrenlivinginruralkenyancoast AT kipkemoipatricia validityandreliabilityoftheneurodevelopmentalscreeningtoolndstinscreeningforneurodevelopmentaldisordersinchildrenlivinginruralkenyancoast AT kariukisymonm validityandreliabilityoftheneurodevelopmentalscreeningtoolndstinscreeningforneurodevelopmentaldisordersinchildrenlivinginruralkenyancoast AT abubakaramina validityandreliabilityoftheneurodevelopmentalscreeningtoolndstinscreeningforneurodevelopmentaldisordersinchildrenlivinginruralkenyancoast AT gonajoseph validityandreliabilityoftheneurodevelopmentalscreeningtoolndstinscreeningforneurodevelopmentaldisordersinchildrenlivinginruralkenyancoast AT philipsowenjacqueline validityandreliabilityoftheneurodevelopmentalscreeningtoolndstinscreeningforneurodevelopmentaldisordersinchildrenlivinginruralkenyancoast AT newtoncharlesr validityandreliabilityoftheneurodevelopmentalscreeningtoolndstinscreeningforneurodevelopmentaldisordersinchildrenlivinginruralkenyancoast |